ANPA-0073
ANPA-0073
PHASE1
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Formulations[{"id":"anpa-oral-1","route":"ORAL","device":"Tablet","setting":"PATIENT_SELF","duration":null,"freq
Mechanism: Apelin receptor agonist
Expert: Biased agonist of the apelin receptor (APJR/APJ) that may selectively mobilize fat stores while sparing lean muscle mass, addressing a key limitation of current weight loss therapies.
Everyday: A drug that activates the apelin pathway to promote selective fat loss while preserving muscle mass.
Targets: ["APJ"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| Muscle-sparing WL | PHASE1 | Phase 1 SAD/MAD (complete) | [] |
Upcoming Catalysts (1)
ANPA-0073 - Muscle-Sparing Weight Loss - Ph2 Decision
2026
Notes
Phase 2 ready. Biased apelin receptor (APJR) agonist. Phase 1 ascending-dose study complete with no serious adverse events. Targets selective fat mobilization while preserving lean muscle mass. Chronic GLP-tox studies completed end 2025.
Data from Supabase · Updated 2026-03-24